Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Equity

v3.3.1.900
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
EirGen Pharma Limited
Bio-Reference Laboratories, Inc.
OPKO Brazil
OPKO Renal
OPKO Biologics
OPKO Health Europe
OPKO Uruguay Ltda.
Inspiro
Common Stock
Common Stock
EirGen Pharma Limited
Common Stock
Bio-Reference Laboratories, Inc.
Common Stock
OPKO Brazil
Common Stock
OPKO Renal
Common Stock
OPKO Biologics
Common Stock
OPKO Health Europe
Treasury
Treasury
OPKO Health Europe
Treasury
OPKO Uruguay Ltda.
Treasury
Inspiro
Additional Paid-In Capital
Additional Paid-In Capital
EirGen Pharma Limited
Additional Paid-In Capital
Bio-Reference Laboratories, Inc.
Additional Paid-In Capital
OPKO Brazil
Additional Paid-In Capital
OPKO Renal
Additional Paid-In Capital
OPKO Biologics
Additional Paid-In Capital
OPKO Health Europe
Additional Paid-In Capital
OPKO Uruguay Ltda.
Additional Paid-In Capital
Inspiro
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Noncontrolling Interests
Series D Preferred Stock
Series D Preferred Stock
Common Stock
Series D Preferred Stock
Additional Paid-In Capital
Notes
Notes
Common Stock
Notes
Additional Paid-In Capital
Beginning balance at Dec. 31, 2012 $ 178,894                 $ 3,056             $ (7,457)       $ 565,201                 $ 7,356 $ (388,770) $ (492)            
Beginning balance, shares at Dec. 31, 2012                   305,560,763             (2,293,056)                                          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                                            
Equity-based compensation expense 10,983                                       10,983                                  
Exercise of Common Stock options and warrants 23,424                 $ 107                     23,317                                  
Exercise of Common Stock options, shares                   10,732,745                                                        
Preferred Stock dividend                                                                 $ (3,015)   $ (3,015)      
Conversion of Preferred Stock                                                                 $ 24,386 $ 113 $ 24,273 $ 20,839 $ 24 $ 20,815
Conversion of Preferred Stock, shares                                                                   11,290,320     2,396,145  
Issuance of Common Stock in connection with acquisition       $ 435 $ 146,902 $ 586,643             $ 1 $ 205 $ 637                 $ 434 $ 146,697 $ 586,006                        
Issuance of Common Stock in connection with acquisition, shares                         64,684 20,517,030 63,670,805                                              
Issuance of Common Stock in connection with Deferred Payment             $ 4,435                 $ 5                     $ 4,430                      
Issuance of Common Stock in connection with Deferred Payment, shares                               585,703                                            
Issuance of Treasury Stock in connection with Contingent Consideration             337                     $ 95                 242                      
Issuance of Treasury Stock in connection with Contingent Consideration, shares                                   28,993                                        
Net loss attributable to common shareholders (114,407)                                                           (114,407)              
Net loss attributable to noncontrolling interests (2,939)                                                             (2,939)            
Other comprehensive loss (3,938)                                                         (3,938)                
Ending balance at Dec. 31, 2013 872,979                 $ 4,148             $ (7,362)       1,379,383                 3,418 (503,177) (3,431)            
Ending balance, shares at Dec. 31, 2013                   414,818,195             (2,264,063)                                          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                                            
Equity-based compensation expense 14,737                                       14,737                                  
Exercise of Common Stock options and warrants 12,928                 $ 54                     12,874                                  
Exercise of Common Stock options, shares                   5,392,841                                                        
Issuance of Common Stock in connection with acquisition 95,665       21,155     $ 159 $ 8,566 $ 110       $ 22         $ 61 $ 3,250 95,555       21,133     $ 98 $ 5,316                  
Issuance of Common Stock in connection with acquisition, shares                   10,974,431       2,236,210         19,140 999,556                                    
Net loss attributable to common shareholders (171,666)                                                           (171,666)              
Net loss attributable to noncontrolling interests (2,972)                                                             (2,972)            
Other comprehensive loss (15,810)                                                         (15,810)                
Ending balance at Dec. 31, 2014 835,741 [1]                 $ 4,334             $ (4,051)       1,529,096                 (12,392) (674,843) (6,403)            
Ending balance, shares at Dec. 31, 2014                   433,421,677             (1,245,367)                                          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                                            
Equity-based compensation expense 26,074                                       26,074                                  
Exercise of Common Stock options and warrants $ 25,920                 $ 245                     25,675                                  
Exercise of Common Stock options, shares 6,643,991                 24,467,806                                                        
Issuance of Common Stock in connection with acquisition $ 120,299 $ 33,596 $ 950,010   $ 20,112         $ 81 $ 24 $ 766   $ 12             120,218 $ 33,572 $ 949,244   $ 20,100                          
Issuance of Common Stock in connection with acquisition, shares                   8,118,062 2,420,487 76,566,147   1,194,337                                                
Issuance of Treasury Stock in connection with Contingent Consideration             $ 1,812                     $ 406                 $ 1,406                      
Issuance of Treasury Stock in connection with Contingent Consideration, shares                                   125,000                                        
Net loss attributable to common shareholders (30,028)                                                           (30,028)              
Deconsolidation of SciVac 6,403                                                             6,403            
Net loss attributable to noncontrolling interests (1,400)                                                                          
Other comprehensive loss (10,145)                                                         (10,145)                
Ending balance at Dec. 31, 2015 $ 1,979,794 [1]                 $ 5,462             $ (3,645)       $ 2,705,385                 $ (22,537) $ (704,871) $ 0            
Ending balance, shares at Dec. 31, 2015                   546,188,516             (1,120,367)                                          
[1] As of December 31, 2014, total assets include $7.6 million and total liabilities include $12.1 million related to SciVac Ltd (“SciVac”). SciVac was a consolidated variable interest entity which we deconsolidated in July 2015. Refer to Note 4. SciVac’s consolidated assets were owned by SciVac and SciVac’s consolidated liabilities had no recourse against us.